{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:03:50Z","timestamp":1789916630365,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["pericles.pericles-gcp.literatumonline.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recombinant zoster vaccine (RZV) is recommended for all adults \u226519\u2009years of age who are at increased risk for HZ, including patients with inflammatory bowel disease (IBD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model was constructed to compare the RZV cost\u2010effectiveness with no vaccination in patients with Crohn's Disease (CD) and ulcerative colitis (UC). A simulated cohort of 1 million patients was used for each IBD group at ages 18, 30, 40, and 50. The primary objective of this analysis was to compare RZV cost\u2010effectiveness in patients with CD and UC, comparing vaccination to no vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, vaccination is cost\u2010effective for both CD and UC, with the incremental cost\u2010effectiveness ratio (ICERs) below $100,000\/quality\u2010adjusted life years (QALY) for all age cohorts. For patients with CD, 30\u2009years of age and older, and those with UC 40\u2009years and older, vaccination was both more effective and less expensive than the non\u2010vaccinated strategy (CD \u226530: ICERs $6183\u2013$24,878 and UC \u226540: ICERs $9163\u2013$19,655). However, for CD patients under 30 (CD 18: ICER $2098) and UC patients under 40 (UC\u00a0=\u00a018: ICER $11,609, and UC\u00a0=\u00a030: $1343), costs were greater for vaccinated patients, but there was an increase in QALY. One\u2010way sensitivity analysis of age indicates that cost break\u2010even occurs at age 21.8 for the CD group and 31.5 for the UC group. In probabilistic sensitivity analysis, 92% of both CD and UC simulations indicated that vaccination was preferred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our model, vaccination with RZV was cost\u2010effective for all adult patients with IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.17454","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T07:23:46Z","timestamp":1678433026000},"page":"1326-1334","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["<scp>Cost\u2010effectiveness<\/scp>\n                    of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease"],"prefix":"10.1111","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-6611","authenticated-orcid":false,"given":"Freddy","family":"Caldera","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology University of Wisconsin\u2014Madison, School of Medicine &amp; Public Health  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Spaulding","sequence":"additional","affiliation":[{"name":"Division of Health Care Delivery Research Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Borah","sequence":"additional","affiliation":[{"name":"Division of Health Care Delivery Research Mayo Clinic  Rochester Minnesota USA"},{"name":"Kern Center for the Science of Health Care Delivery Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Moriarty","sequence":"additional","affiliation":[{"name":"Kern Center for the Science of Health Care Delivery Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhu","sequence":"additional","affiliation":[{"name":"Kern Center for the Science of Health Care Delivery Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Hayney","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin\u2014Madison, School of Medicine &amp; Public Health  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000713"},{"issue":"5","key":"e_1_2_13_3_1","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz R","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000446"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.01.359"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.091711"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0550-8"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1090"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.05.024"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.09.019"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.12.052"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12182"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2"},{"key":"e_1_2_13_15_1","unstructured":"European Commission \u2010 Public Health Community register of medicinal products for human use \u2010 Product information \u2010 Shingrix.2018April 03 [cited 2020 September 16]. Available from:http:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/html\/h1272.htm"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/514342"},{"key":"e_1_2_13_17_1","unstructured":"Statistics USBoL. Consumer Price Index.2021[cited 2021 January 15]. Available from:https:\/\/www.bls.gov\/cpi\/data.htm."},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2018.1447828"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy311"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","unstructured":"YawnBP SaddierP WollanPC SauverJLS KurlandMJ SyLS.A population\u2010based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Paper presented at: Mayo Clinic Proceedings2007.","DOI":"10.4065\/82.11.1341"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7431"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","unstructured":"SecurityS.Actuarial Life Table. Social Security.2021[cited 2021 January 15]. Available from:https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html","DOI":"10.1016\/S1353-4858(21)00101-X"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.005"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1_3"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-2347"},{"key":"e_1_2_13_27_1","unstructured":"UK Health Security Agency.Shingles: The green book chapter 28a.2021https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1012943\/Green_book_of_immunisation_28a_Shingles.pdf"},{"key":"e_1_2_13_28_1","unstructured":"European Medicines Agency.Shingrix.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy131"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17379"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy232"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy387"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.17454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.17454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.17454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T11:31:47Z","timestamp":1693913507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.17454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/apt.17454"],"URL":"https:\/\/doi.org\/10.1111\/apt.17454","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"2022-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}